Tekla Capital Management LLC Reata Pharmaceuticals Inc Transaction History

Tekla Capital Management LLC

  • $2.53 Billion
  • Q2 2023

A detailed history of Tekla Capital Management LLC transactions in Reata Pharmaceuticals Inc stock. As of the latest transaction made, Tekla Capital Management LLC holds 34,250 shares of RETA stock, worth $0. This represents 0.14% of its overall portfolio holdings.

Number of Shares
34,250
Previous 17,850 91.88%
Holding current value
$0
Previous $1.62 Million 115.29%
% of portfolio
0.14%
Previous 0.06%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023
BUY
$79.22 - $105.37 $1.3 Million - $1.73 Million
16,400 Added 91.88%
34,250 $3.49 Million
Q1 2023

May 10, 2023
BUY
$30.85 - $93.17 $550,672 - $1.66 Million
17,850 New
17,850 $1.62 Million
Q3 2021

Nov 12, 2021
SELL
$100.0 - $143.02 $3.82 Million - $5.47 Million
-38,219 Closed
0 $0
Q4 2020

Feb 12, 2021
SELL
$102.03 - $184.62 $3.9 Million - $7.06 Million
-38,221 Reduced 50.0%
38,219 $4.73 Million
Q3 2020

Nov 13, 2020
BUY
$93.53 - $163.34 $2.39 Million - $4.17 Million
25,533 Added 50.16%
76,440 $7.45 Million
Q2 2020

Aug 13, 2020
BUY
$126.3 - $176.56 $1.99 Million - $2.79 Million
15,778 Added 44.91%
50,907 $7.94 Million
Q1 2020

May 14, 2020
BUY
$124.16 - $247.74 $1.08 Million - $2.16 Million
8,717 Added 33.0%
35,129 $5.07 Million
Q4 2019

Feb 13, 2020
BUY
$74.57 - $217.92 $1.97 Million - $5.76 Million
26,412 New
26,412 $5.4 Million

Others Institutions Holding RETA

# of Institutions
5
Shares Held
62.7K
Call Options Held
0
Put Options Held
0
View Full List

About REATA PHARMACEUTICALS INC

RETA Quotes by TradingView
  • Ticker RETA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,583,200
  • Description
  • Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...
More about RETA
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email